-
1
-
-
77952547165
-
Therapy for fungal diseases: Opportunities and priorities
-
Denning DW, Hope WW. 2010. Therapy for fungal diseases: opportunities and priorities. Trends Microbiol 18:195-204. http://dx.doi.org/10.1016/j.tim.2010.02.004.
-
(2010)
Trends Microbiol
, vol.18
, pp. 195-204
-
-
Denning, D.W.1
Hope, W.W.2
-
2
-
-
84903465253
-
Fourth European Conference on Infections in Leukaemia (ECIL-4): Guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation
-
Groll AH, Castagnola E, Cesaro S, Dalle J-H, Engelhard D, Hope W, Roilides E, Styczynski J, Warris A, Lehrnbecher T. 2014. Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation. Lancet Oncol 15:e327- e340. http://dx.doi.org/10.1016/S1470-2045(14)70017-8.
-
(2014)
Lancet Oncol
, vol.15
, pp. e327-e340
-
-
Groll, A.H.1
Castagnola, E.2
Cesaro, S.3
Dalle, J.-H.4
Engelhard, D.5
Hope, W.6
Roilides, E.7
Styczynski, J.8
Warris, A.9
Lehrnbecher, T.10
-
3
-
-
39449095735
-
Treatment of aspergillosis: Clinical practice guidelines of the Infectious Diseases Society of America
-
Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Segal BH, Steinbach WJ, Stevens DA, van Burik JA, Wingard JR, Patterson TF. 2008. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 46:327-360. http://dx.doi.org/10.1086/525258.
-
(2008)
Clin Infect Dis
, vol.46
, pp. 327-360
-
-
Walsh, T.J.1
Anaissie, E.J.2
Denning, D.W.3
Herbrecht, R.4
Kontoyiannis, D.P.5
Marr, K.A.6
Morrison, V.A.7
Segal, B.H.8
Steinbach, W.J.9
Stevens, D.A.10
Van Burik, J.A.11
Wingard, J.R.12
Patterson, T.F.13
-
4
-
-
60549086769
-
The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers
-
Wang G, Lei HP, Li Z, Tan ZR, Guo D, Fan L, Chen Y, Hu DL, Wang D, Zhou HH. 2009. The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers. Eur J Clin Pharmacol 65:281-285. http://dx.doi.org/10.1007/s00228-008-0574-7.
-
(2009)
Eur J Clin Pharmacol
, vol.65
, pp. 281-285
-
-
Wang, G.1
Lei, H.P.2
Li, Z.3
Tan, Z.R.4
Guo, D.5
Fan, L.6
Chen, Y.7
Hu, D.L.8
Wang, D.9
Zhou, H.H.10
-
6
-
-
72049130592
-
Voricona- zole pharmacokinetics and pharmacodynamics in children
-
Neely M, Rushing T, Kovacs A, Jelliffe R, Hoffman J. 2010. Voricona- zole pharmacokinetics and pharmacodynamics in children. Clin Infect Dis 50:27-36. http://dx.doi.org/10.1086/648679.
-
(2010)
Clin Infect Dis
, vol.50
, pp. 27-36
-
-
Neely, M.1
Rushing, T.2
Kovacs, A.3
Jelliffe, R.4
Hoffman, J.5
-
7
-
-
84912124222
-
Inflammation is associated with voriconazole trough concentrations
-
van Wanrooy MJP, Span LFR, Rodgers MGG, van den Heuvel ER, Uges DR a, van der Werf TS, Kosterink JGW, Alffenaar J-WC. 2014. Inflammation is associated with voriconazole trough concentrations. Antimicrob Agents Chemother 58:7098-7101. http://dx.doi.org/10.1128/AAC.03820-14.
-
(2014)
Antimicrob Agents Chemother
, vol.58
, pp. 7098-7101
-
-
Van Wanrooy, M.J.P.1
Span, L.F.R.2
Rodgers, M.G.G.3
Van Den Heuvel, E.R.4
Uges, D.R.5
Van Der Werf, T.S.6
Kosterink, J.G.W.7
Alffenaar, J.-W.C.8
-
8
-
-
65549159077
-
Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered, agents
-
Brüggemann RJM, Alffenaar JC, Blijlevens NMA, Billaud EM, Kosterink JGW, Verweij PE, Burger DM. 2009. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis 48:1441-1458. http://dx.doi.org/10.1086/598327.
-
(2009)
Clin Infect Dis
, vol.48
, pp. 1441-1458
-
-
Brüggemann, R.J.M.1
Alffenaar, J.C.2
Blijlevens, N.M.A.3
Billaud, E.M.4
Kosterink, J.G.W.5
Verweij, P.E.6
Burger, D.M.7
-
9
-
-
84898452706
-
Therapeutic drug monitoring (TDM) of antifungal agents: Guidelines from the British Society for Medical Mycology
-
Ashbee HR, Barnes RA, Johnson EM, Richardson MD, Gorton R, Hope WW. 2014. Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. J Antimicrob Chemother 69:1162-1176. http://dx.doi.org/10.1093/jac/dkt508.
-
(2014)
J Antimicrob Chemother
, vol.69
, pp. 1162-1176
-
-
Ashbee, H.R.1
Barnes, R.A.2
Johnson, E.M.3
Richardson, M.D.4
Gorton, R.5
Hope, W.W.6
-
10
-
-
84875135343
-
Software for dosage individualization of voriconazole for immunocompromised patients
-
Hope WW, Vanguilder M, Donnelly JP, Blijlevens NM, Brüggemann RJM, Jelliffe RW, Neely MN, Bruggemann RJ. 2013. Software for dosage individualization of voriconazole for immunocompromised patients. Antimicrob Agents Chemother 57:1888-1894. http://dx.doi.org/10.1128/AAC.02025-12.
-
(2013)
Antimicrob Agents Chemother
, vol.57
, pp. 1888-1894
-
-
Hope, W.W.1
Vanguilder, M.2
Donnelly, J.P.3
Blijlevens, N.M.4
Brüggemann, R.J.M.5
Jelliffe, R.W.6
Neely, M.N.7
Bruggemann, R.J.8
-
11
-
-
84929643042
-
Achieving target voriconazole concentrations more accurately in children and adolescents
-
Neely M, Margol A, Fu X, van Guilder M, Bayard D, Schumitzky A, Orbach R, Liu S, Louie S, Hope W. 2015. Achieving target voriconazole concentrations more accurately in children and adolescents. Antimicrob Agents Chemother 59:3090-3097. http://dx.doi.org/10.1128/AAC.00032-15.
-
(2015)
Antimicrob Agents Chemother
, vol.59
, pp. 3090-3097
-
-
Neely, M.1
Margol, A.2
Fu, X.3
Van Guilder, M.4
Bayard, D.5
Schumitzky, A.6
Orbach, R.7
Liu, S.8
Louie, S.9
Hope, W.10
-
12
-
-
46249126149
-
Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG)
-
De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, Pappas PG, Maertens J, Lortholary O, Kauffman CA, Denning DW, Patterson TF, Maschmeyer G, Bille J, Dismukes WE, Herbrecht R, Hope WW, Kibbler CC, Kullberg BJ, Marr KA, Munoz P, Odds FC, Perfect JR, Restrepo A, Ruhnke M, Segal BH, Sobel JD, Sorrell TC, Viscoli C, Wingard JR, Zaoutis T, Bennett JE, Pauw De B, Mun P. 2008. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG). Clin Infect Dis 46:1813- 1821. http://dx.doi.org/10.1086/588660.
-
(2008)
Clin Infect Dis
, vol.46
, pp. 1813-1821
-
-
De Pauw, B.1
Walsh, T.J.2
Donnelly, J.P.3
Stevens, D.A.4
Edwards, J.E.5
Calandra, T.6
Pappas, P.G.7
Maertens, J.8
Lortholary, O.9
Kauffman, C.A.10
Denning, D.W.11
Patterson, T.F.12
Maschmeyer, G.13
Bille, J.14
Dismukes, W.E.15
Herbrecht, R.16
Hope, W.W.17
Kibbler, C.C.18
Kullberg, B.J.19
Marr, K.A.20
Munoz, P.21
Odds, F.C.22
Perfect, J.R.23
Restrepo, A.24
Ruhnke, M.25
Segal, B.H.26
Sobel, J.D.27
Sorrell, T.C.28
Viscoli, C.29
Wingard, J.R.30
Zaoutis, T.31
Bennett, J.E.32
Pauw, D.B.33
Mun, P.34
more..
-
13
-
-
33846450646
-
Pathogenesis of Aspergillus fumigatus and the kinetics of galactomannan in an in vitro model of early invasive pulmonary aspergillosis: Implications for antifungal therapy
-
Hope WW, Kruhlak MJ, Lyman CA, Petraitiene R, Petraitis V, Francesconi A, Kasai M, Mickiene D, Sein T, Peter J, Kelaher AM, Hughes JE, Cotton MP, Cotten CJ, Bacher J, Tripathi S, Bermudez L, Maugel TK, Zerfas PM, Wingard JR, Drusano GL, Walsh TJ. 2007. Pathogenesis of Aspergillus fumigatus and the kinetics of galactomannan in an in vitro model of early invasive pulmonary aspergillosis: implications for antifungal therapy. J Infect Dis 195:455- 466. http://dx.doi.org/10.1086/510535.
-
(2007)
J Infect Dis
, vol.195
, pp. 455-466
-
-
Hope, W.W.1
Kruhlak, M.J.2
Lyman, C.A.3
Petraitiene, R.4
Petraitis, V.5
Francesconi, A.6
Kasai, M.7
Mickiene, D.8
Sein, T.9
Peter, J.10
Kelaher, A.M.11
Hughes, J.E.12
Cotton, M.P.13
Cotten, C.J.14
Bacher, J.15
Tripathi, S.16
Bermudez, L.17
Maugel, T.K.18
Zerfas, P.M.19
Wingard, J.R.20
Drusano, G.L.21
Walsh, T.J.22
more..
-
14
-
-
27444447144
-
Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: A prospective feasibility study
-
Maertens J, Theunissen K, Verhoef G, Verschakelen J, Lagrou K, Verbeken E, Wilmer A, Verhaegen J, Boogaerts M, Eldere Van J. 2005. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: A prospective feasibility study Clin Infect Dis 41:1242-1250.
-
(2005)
Clin Infect Dis
, vol.41
, pp. 1242-1250
-
-
Maertens, J.1
Theunissen, K.2
Verhoef, G.3
Verschakelen, J.4
Lagrou, K.5
Verbeken, E.6
Wilmer, A.7
Verhaegen, J.8
Boogaerts, M.9
Eldere, V.J.10
-
15
-
-
80052426714
-
Earlier response assessment in invasive aspergillosis based on the kinetics of serum aspergillus galactomannan: Proposal for a new definition
-
Nouér SA, Nucci M, Kumar NS, Grazziutti M, Barlogie B, Anaissie E. 2011. Earlier response assessment in invasive aspergillosis based on the kinetics of serum aspergillus galactomannan: Proposal for a new definition. Clin Infect Dis 53:671-676. http://dx.doi.org/10.1093/cid/cir441.
-
(2011)
Clin Infect Dis
, vol.53
, pp. 671-676
-
-
Nouér, S.A.1
Nucci, M.2
Kumar, N.S.3
Grazziutti, M.4
Barlogie, B.5
Anaissie, E.6
-
16
-
-
71249154511
-
Method for therapeutic drug monitoring of azole antifungal drugs in human serum using LC/MS/MS
-
Alffenaar JW, Wessels AM, van Hateren K, Greijdanus B, Kosterink JG, Uges DR. 2010. Method for therapeutic drug monitoring of azole antifungal drugs in human serum using LC/MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci 878:39-44. http://dx.doi.org/10.1016/j.jchromb.2009.11.017.
-
(2010)
J Chromatogr B Analyt Technol Biomed Life Sci
, vol.878
, pp. 39-44
-
-
Alffenaar, J.W.1
Wessels, A.M.2
Van Hateren, K.3
Greijdanus, B.4
Kosterink, J.G.5
Uges, D.R.6
-
17
-
-
84863817675
-
Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R
-
Neely MN, van Guilder MG, Yamada WM, Schumitzky A, Jelliffe RW. 2012. Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R. Ther Drug Monit 34:467-476. http://dx.doi.org/10.1097/FTD.0b013e31825c4ba6.
-
(2012)
Ther Drug Monit
, vol.34
, pp. 467-476
-
-
Neely, M.N.1
Van Guilder, M.G.2
Yamada, W.M.3
Schumitzky, A.4
Jelliffe, R.W.5
-
18
-
-
39449117139
-
Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes
-
Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. 2008. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 46:201-211. http://dx.doi.org/10.1086/524669.
-
(2008)
Clin Infect Dis
, vol.46
, pp. 201-211
-
-
Pascual, A.1
Calandra, T.2
Bolay, S.3
Buclin, T.4
Bille, J.5
Marchetti, O.6
-
19
-
-
31344478761
-
Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities
-
Tan K, Brayshaw N, Tomaszewski K, Troke P, Wood N. 2006. Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. J Clin Pharmacol 46:235-243. http://dx.doi.org/10.1177/0091270005283837.
-
(2006)
J Clin Pharmacol
, vol.46
, pp. 235-243
-
-
Tan, K.1
Brayshaw, N.2
Tomaszewski, K.3
Troke, P.4
Wood, N.5
-
20
-
-
0036498964
-
Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis
-
Denning DW, Ribaud P, Milpied N, Caillot D, Herbrecht R, Thiel E, Haas A, Ruhnke M, Lode H. 2002. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 34:563-571. http://dx.doi.org/10.1086/324620.
-
(2002)
Clin Infect Dis
, vol.34
, pp. 563-571
-
-
Denning, D.W.1
Ribaud, P.2
Milpied, N.3
Caillot, D.4
Herbrecht, R.5
Thiel, E.6
Haas, A.7
Ruhnke, M.8
Lode, H.9
-
21
-
-
0037043655
-
Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis
-
Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, Kern WV, Marr KA, Ribaud P, Lortholary O, Sylvester R, Rubin RH, Wingard JR, Stark P, Durand C, Caillot D, Thiel E, Chandrasekar PH, Hodges MR, Schlamm HT, Troke PF, de Pauw B. 2002. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347:408 - 415. http://dx.doi.org/10.1056/NEJMoa020191.
-
(2002)
N Engl J Med
, vol.347
, pp. 408-415
-
-
Herbrecht, R.1
Denning, D.W.2
Patterson, T.F.3
Bennett, J.E.4
Greene, R.E.5
Oestmann, J.W.6
Kern, W.V.7
Marr, K.A.8
Ribaud, P.9
Lortholary, O.10
Sylvester, R.11
Rubin, R.H.12
Wingard, J.R.13
Stark, P.14
Durand, C.15
Caillot, D.16
Thiel, E.17
Chandrasekar, P.H.18
Hodges, M.R.19
Schlamm, H.T.20
Troke, P.F.21
De Pauw, B.22
more..
|